Moderna lowers forecast for 2021 COVID-19 vaccine deliveries
Moderna is scaling back expectations for the number of COVID-19 vaccine deliveries it expects to make this year
Your support helps us to tell the story
As your White House correspondent, I ask the tough questions and seek the answers that matter.
Your support enables me to be in the room, pressing for transparency and accountability. Without your contributions, we wouldn't have the resources to challenge those in power.
Your donation makes it possible for us to keep doing this important work, keeping you informed every step of the way to the November election
Andrew Feinberg
White House Correspondent
Moderna is scaling back expectations for the number of COVID-19 vaccine deliveries it expects to make this year and the revenue it will record from them.
The drugmaker said Thursday that longer delivery lead times for exports and a temporary impact from expanding its fill-finish capacity may shift some deliveries to early 2022. The company now expects full-year, 2021 product sales of between $15 billion and $18 billion.
That’s down from a prediction for $20 billion in sales that it made in August.
Moderna’s COVID-19 vaccine is the only product the drugmaker has on the market. It brought in $4.81 billion in sales during the third quarter, up from $4.2 billion the previous quarter.
The Cambridge Massachusetts company also reported on Thursday third-quarter results that missed expectations.
Company shares fell almost 11% before the opening bell.
Moderna Inc. makes one of three COVID-19 vaccines currently being used in the United States The others are made by Pfizer Inc. and Johnson & Johnson.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.